- Home
- ONMD vs IBIO Comparison
ONMD vs IBIO Comparison
Compare ONMD & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- IBIO
- Stock Information
- Founded
- ONMD 2006
- IBIO 2008
- Country
- ONMD United States
- IBIO United States
- Employees
- ONMD N/A
- IBIO N/A
- Industry
- ONMD
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ONMD
- IBIO Health Care
- Exchange
- ONMD Nasdaq
- IBIO Nasdaq
- Market Cap
- ONMD 23.9M
- IBIO 24.3M
- IPO Year
- ONMD N/A
- IBIO N/A
- Fundamental
- Price
- ONMD $1.40
- IBIO $2.48
- Analyst Decision
- ONMD
- IBIO Strong Buy
- Analyst Count
- ONMD 0
- IBIO 3
- Target Price
- ONMD N/A
- IBIO $4.87
- AVG Volume (30 Days)
- ONMD 351.4K
- IBIO 104.4K
- Earning Date
- ONMD 12-31-2024
- IBIO 02-07-2025
- Dividend Yield
- ONMD N/A
- IBIO N/A
- EPS Growth
- ONMD N/A
- IBIO N/A
- EPS
- ONMD 0.01
- IBIO N/A
- Revenue
- ONMD $957,651.00
- IBIO $175,000.00
- Revenue This Year
- ONMD N/A
- IBIO N/A
- Revenue Next Year
- ONMD N/A
- IBIO N/A
- P/E Ratio
- ONMD $169.88
- IBIO N/A
- Revenue Growth
- ONMD 1.36
- IBIO 250.00
- 52 Week Low
- ONMD $0.42
- IBIO $1.02
- 52 Week High
- ONMD $3.37
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- ONMD 77.16
- IBIO 48.23
- Support Level
- ONMD $0.90
- IBIO $2.26
- Resistance Level
- ONMD $0.98
- IBIO $2.75
- Average True Range (ATR)
- ONMD 0.17
- IBIO 0.23
- MACD
- ONMD 0.02
- IBIO -0.02
- Stochastic Oscillator
- ONMD 79.91
- IBIO 36.36
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.